SEATTLE — In this Healio Video Perspective from the ASRS meeting, Ashkan M. Abbey, MD, FASRS, FAAO, overviews data evaluating subretinal delivery of RGX-314 gene therapy for the treatment of neovascular age-related macular degeneration.
The phase 2 study compared RGX-314 (Regenxbio/AbbVie) produced in a clinical research fashion with a manufacturing technique called Hyperstack and RGX-314 produced by a bioreactor commercial-based process. Both groups had a high-dose and low-dose arm.
“We can see that this could be an exciting option for our patients in the future in order to